IP Library Granted Patent US 10,364,288
Granted Patent B2
US 10,364,288 · App. 14/890,653 · Granted Jul 30, 2019

Anti-GPIIB/IIIA antibodies or uses thereof

Inventors: Joe Salas (Wayland, MA); Siyuan Tan (Lexington, MA); Robert Peters (Needham, MA)
Assignee: Biogen MA Inc.
C07K16/2848C07K14/755C12N9/6408C12N9/6437C12Y304/21021C07K2317/24C07K2317/565C07K2317/92C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,364,288
App. No.
14/890,653
Granted
Jul 30, 2019
Kind
B2
Abstract

The present invention provides antibodies and antigen-binding molecules thereof which specifically bind the α and/or β subunits of the non-active form of the GPIIb/IIIIa receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties and used, for example, as targeting moieties. The invention also includes methods for screening for these antibodies, as well as methods of making and methods of using chimeric molecules derived from the antibodies.

Claims (15)

1. An antibody or antigen-binding fragment thereof that binds to glycoprotein IIb/IIIa (GPIIb/IIIa), wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence AYAMS (SEQ ID NO:31);

the VH CDR2 comprises the amino acid sequence SISSGGTTYYPDSVKR (SEQ ID NO:32); and

the VH CDR3 comprises the amino acid sequence GGDYGYALDY (SEQ ID NO:33); and

wherein the antibody or the antigen-binding fragment thereof comprises a light chain variable region (VL) comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence RASSSVNYMY (SEQ ID NO:34);

the VL CDR2 comprises the amino acid sequence YTSNLAP (SEQ ID NO:35); and

the VL CDR3 comprises the amino acid sequence QQFSSSPWT (SEQ ID NO:36).

2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the VH comprises the amino acid sequence set forth in SEQ ID NO:1 and the VL comprises the amino acid sequence set forth in SEQ ID NO:2.

3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding molecule thereof comprises or consists of a single chain Fv, a diabody, a minibody, a polypeptide chain of an antibody, an F(ab′) 2 , or, an F(ab).

4. The antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding molecule thereof comprises or consists of a single chain Fv, a diabody, a minibody, a polypeptide chain of an antibody, an F(ab′) 2 , or, an F(ab).

5. A pharmaceutical composition comprising the antibody or antigen-binding molecule thereof of claim 1 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising the antibody or antigen-binding molecule thereof of claim 2 and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising the antibody or antigen-binding molecule thereof of claim 3 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising the antibody or antigen-binding molecule thereof of claim 4 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2016
From: SALAS, JOE; TAN, SIYUAN; PETERS, ROBERT
To: BIOGEN MA INC.
Reel/Frame 037776/0909 →
Continuity (2)
Provisional Application 61827165 · May 24, 2013
Related Publication 20160115234A1 · Apr 28, 2016